Igor Barjaktarevic
Pulmonary Disease · Los Angeles, CANPI 1932345105
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.7%. Reporting peaked in 2024 at $95,453 and has fallen 55.4% since, to $42,525 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 296 payments — averaging $1137.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$70K
- Grifols USA, LLC$60K
- Mylan Specialty L.p.$48K
- AstraZeneca$39K
- CSL Behring$18K
- GSK$18K
- plus $85K from 12 others
Across 102 payments — averaging $15,404 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mylan Specialty L.p.$345K
- Roche Products Limited$323K
- Amgen$267K
- Takeda Pharmaceuticals U.S.A., Inc.$231K
- Grifols Therapeutics LLC$124K
- Genentech, Inc.$81K
- plus $200K from 7 others
What the payments were for
- Consulting fees$177,61253%
- Speaking & faculty fees$129,17638%
- Travel & lodging$23,5607%
- Food & beverage$6,4192%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 29 | $69,650 |
| Grifols USA, LLC | 59 | $59,834 |
| Mylan Specialty L.p. | 66 | $47,607 |
| AstraZeneca | 46 | $38,787 |
| CSL Behring | 5 | $18,048 |
| GSK | 19 | $17,890 |
| GE HealthCare | 12 | $16,710 |
| Verona Pharma, Inc. | 12 | $15,350 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $14,218 |
| Regeneron | 7 | $11,111 |
| Genentech USA, Inc. | 8 | $7,804 |
| Astrazeneca UK Limited | 2 | $6,981 |
| Regeneron Healthcare Solutions, Inc. | 6 | $4,483 |
| Aero US Inc | 2 | $3,306 |
| Grifols Shared Services North America, Inc. | 1 | $2,460 |
| Vertex | 10 | $1,354 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,200 |
| Pulmonx Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolastin-C Liquid$55,111
- Yupelri$46,517
- DUPIXENT$39,462
- Zemaira$18,035
- Ohtuvayre$15,266
- IMFINZI$8,452
- AEROGEN SOLO NEBULIZER SYSTEM$6,612
- FASENRA$6,498
- BREZTRI AEROSPHERE$6,419
- BREZTRI$6,176
- TRELEGY ELLIPTA$6,134
- GLASSIA$3,979
- AEROGEN USB CONTROLLER SYSTEM$3,306
- AEROGEN SOLO; AEROGEN ULTRA$3,306
- NUCALA$3,250
- Prolastin-C$1,925
- TEZSPIRE$1,880
- Tavalisse$1,200
How this compares
$336,811 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $35,538 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $20,671 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $8,720 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $832 |
| Azelastine Hcl | 17 | $583 |
| Fluticasone Propionate | 20 | $375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $17,890 | $56,20969 claims |
| AstraZenecaBreztri Aerosphere | $38,787 | $8,72012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$1.3M
- Victor TapsonLos Angeles$514K
- Rajan SaggarLos Angeles$480K
- Scott OhLos Angeles$252K
- Christopher CooperLos Angeles$239K
- John BelperioLos Angeles$224K
- Robert StrieterLos Angeles$173K
- Roy ArtalLos Angeles$152K
- Donald TashkinLos Angeles$141K
- Jameel HouraniLos Angeles$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.